News Update
Widely hailed as the future of phase II drug development, the adaptive I-SPY2 platform trial has set a new benchmark for efficiency, through innovation in trial design and clinical operations.
Come see what I-SPY2 has been up to at the 2018 San Antonio Breast Cancer Symposium with our handy list of posters and presentations.
Personalized serial circulating tumor DNA (ctDNA) analysis in high-risk early stage breast cancer patients to monitor and predict response to neoadjuvant therapy and outcome in the I-SPY 2 TRIAL (PD2-01)
Magbanua M, Brown-Swigart L, Hirst G, et al
Stars at Night Ballroom 3&4 - 3rd Level
Spotlight Session 2 - Biomarkers in Clinical Trials
MRI detection of residual disease following neoadjuvant chemotherapy (NAC) in the I-SPY 2 TRIAL (PD4-03)
Li W, Newitt DC, Yun BL, et al.
Stars at Night Ballroom 3&4 - 3rd Level
Spotlight Session 4 - Breast Cancer Screening and Imaging
-----
Refining neoadjuvant predictors of three year distant metastasis free survival: integrating volume change as measured by MRI with residual cancer burden (P2-07-03)
Hylton NM, Symmans WF, Yau C, et al.
Hall 1
Poster Session 2 - Prognostic and Predictive Factors: Prognostic Factor Index Scores
-----
Role of breast MRI in predicting pathologically negative nodes after neoadjuvant chemotherapy in cN0 patients in the I-SPY 2 trial (PD4-04)
van der Noordaa MEM, Esserman L, Yau C, et al
Stars at Night Ballroom 3&4 - 3rd Level
Spotlight Session 4 - Breast Cancer Screening and Imaging
-----
The impact of local therapy on locoregional recurrence in women with high risk breast cancer in the neoadjuvant I-SPY2 TRIAL (P2-14-01)
Silverstein J, Suleiman L, Yau C, et al.
Hall 1
Poster Session 2 - Treatment: Surgery
Identifying breast cancer molecular phenotypes to predict response in a modern treatment landscape: lessons from ~1000 patients across 10 arms of the I-SPY 2 TRIAL (P3-10-02)
Wolf DM, Yau C, Wulfkhule J, et al.
Hall 1
Poster Session 3 - Prognostic and Predictive Factors: Predictive Biomarkers for Targeted Therapies
-----
Expression-based immune signatures as predictors of neoadjuvant targeted-/chemo-therapy response: Experience from the I-SPY 2 TRIAL of ~1000 patients across 10 therapies (P3-10-06)
Yau C, Wolf D, Campbell M, et al.
Hall 1
Poster Session 3 - Prognostic and Predictive Factors: Predictive Biomarkers for Targeted Therapies
-----
2018 San Antonio Breast Cancer Symposium
LIV-1 Expression in Primary Breast Cancers in the I-SPY 2 TRIAL (P3-10-14)
Yau C, Brown-Swigart L, Asare S, et al/
Hall 1
Poster Session 3 - Prognostic and Predictive Factors: Predictive Biomarkers for Targeted Therapies
Molecular subtypes of invasive lobular breast cancer in the I-SPY2 Trial (PD7-06)
Zhu Z, Yau C, van ’t Veer L, et al.
Stars at Night Ballroom 1&2 - 3rd Level
Spotlight Session 7 - Lobular Breast Cancer
The use of 18F-FDG PET/CT as an initial staging procedure for stage II-III breast cancer reduces false positives, costs, and time to treatment: a multicenter value analysis in the I-SPY2 trial (P5-15-01)
Hyland C, Varghese F, Yau C, et al.
Hall 1
Poster Session 5 - Psychosocial, QOL, and Educational Aspects: Cost Effectiveness
Karyn DiGiorgio
Quantum Leap Healthcare Collaborative
karyn.digiorgio@quantumleaphealth.org
Sponsored by Quantum Leap Healthcare Collaborative™, a 501C(3) charitable organization accelerating the union of high-impact clinical research and patient care to improve and save lives.
